nach oben

Erschienen in:

09.04.2020 | original article

No evidence of occult HBV infection in population born after mass vaccination

verfasst von: Mohammad Reza Aghasadeghi, Arezoo Aghakhani, Setareh Mamishi, Farahnaz Bidari-Zerehpoosh, Mohammad-Taghi Haghi Ashtiani, Shahram Sabeti, Mohammad Banifazl, Afsaneh Karami, Anahita Bavand, Amitis Ramezani

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 9-10/2020

Einloggen, um Zugang zu erhalten

Summary

Despite access to efficient hepatitis B virus (HBV) vaccine and universal immunization schedules, HBV infection remains a global health concern. HBV infection has decreased by this program. Nevertheless, breakthrough infections occur due to generation of occult HBV infection (OBI) and surface gene mutants in the immunized population. We aimed to determine the presence of OBI in a population born after initiation of nationwide HBV vaccination in Tehran, Iran. A HBV mass vaccination schedule was launched in Iran in 1993. For this study, we enrolled 1120 cases younger than 24 years. ELISA was applied to evaluate the presence of HBsAg, anti-HBs and anti-HBc. HBV-DNA presence was determined in all HBsAg-negative cases using nested polymerase chain reaction. The prevalence of HBsAg, anti-HBc and anti-HBs was 0.1, 0.54 and 39.9% respectively. Out of 6 anti-HBc-positive individuals, 4 cases also had anti-HBs. One case revealed HBsAg co-existence and the other one showed isolated anti-HBc. HBV-DNA was not detected in HBsAg-negative specimens. A very low prevalence of HBsAg and isolated anti-HBc was observed and no occult HBV infection was detected. It seems that evasion mutants are not a potential threat for HBV universal immunization efficacy in the vaccinated population.

Vorheriger Artikel Epidemiologic and clinical findings of children with acquired immunodeficiency syndrome in four provinces of Iran

Nächster Artikel My best case: homeopathic management of adverse effects of tamoxifen

El-Seraq HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27. https://doi.org/10.1056/NEJMra1001683.CrossRef

van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One. 2007;2(8):e753. https://doi.org/10.1371/journal.pone.0000753.CrossRefPubMedPubMedCentral

Chang MH. Breakthrough HBV infection in vaccinated children in Taiwan. Surveillance for HBV mutants. Antivir Ther. 2010;15:463–9. https://doi.org/10.3851/IMP1555.CrossRefPubMed

McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow up. Ann Intern Med. 2005;142:333–41. https://doi.org/10.7326/0003-4819-142-5-200503010-00008.CrossRefPubMed

Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis. 1998;27:100–6.CrossRef

Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71(2):397–408.CrossRef

Aghakhani A, Mohraz M, Aghasadeghi MR, Banifazl M, Vahabpour R, et al. Occult hepatitis B virus infection and S gene escape mutants in HIV-infected patients after hepatitis B virus vaccination. Int J STD Aids. 2016;27(11):967–72. https://doi.org/10.1177/0956462415602419.CrossRefPubMed

Aghakhani A, Banifazl M, Kalantar E, Eslamifar A, Ahmadi F, Razeghi E, et al. Occult hepatitis B virus infection in hemodialysis patients with isolated hepatitis B core antibody. A multicenter study. Ther Apher Dial. 2010;14(3):349–53. https://doi.org/10.1111/j.1744-9987.2009.00798.x.CrossRefPubMed

Azadmanesh K, Mohraz M, Aghakhani A, Edalat R, Jam S, Eslamifar A et al. Occult hepatitis B virus infection in HIV-infected patients with isolated hepatitis B core antibody. Intervirology. 2008;51(4):270–4. https://doi.org/10.1159/000160217.CrossRefPubMed

10.

Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology. 2017;65:1451–61.CrossRef

11.

Hsu HY, Chang MH, Ni YH, Chiang CL, Wu JF, Chen HL. Universal infant immunization and occult hepatitis B virus infection in children and adolescents: a population-based study. Hepatology. 2015;61:1183–91.CrossRef

12.

Ramezani A, Aghasadeghi MR, Ahmadi F, Razeghi E, Eslamifar A, Banifazl M, et al. Isolated anti-hbc and occult HBV infection in dialysis patients. Nephrourol Mon. 2014;7(1):e22674. https://doi.org/10.5812/numonthly.22674.CrossRefPubMedPubMedCentral

13.

Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, Ciancio A, et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int. 2015;35:2311–7.CrossRef

14.

Lusida M, Juniastuti, Yano Y. Current hepatitis B virus infection situation in Indonesia and its genetic diversity. World J Gastroenterol. 2016;22(32):7264–74. https://doi.org/10.3748/wjg.v22.i32.7264.CrossRefPubMedPubMedCentral

15.

Ponde RA. Molecular mechanisms underlying HBsAg negativity in occult HBV infection. Eur J Clin Microbiol Infect Dis. 2015;34:1709–31.CrossRef

16.

Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479–86. https://doi.org/10.1016/S1473-3099(02)00345-6.CrossRefPubMed

17.

Kim H, Kim BJ. Association of preS/S mutations with occult hepatitis B virus (HBV) infection in South Korea. Transmission potential of distinct occult HBV variants. Int J Mol Sci. 2015;16(6):13595–609. https://doi.org/10.3390/ijms160613595.CrossRefPubMedPubMedCentral

18.

Teo CG, Locarnini S. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antivir Ther. 2010;15:445–9.CrossRef

19.

Huang C‑H, Yuan Q, Chen PJ, Zhang YL, Chen CR, Zheng QB, et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol. 2012;57(4):720–9.CrossRef

20.

World Health Organization. Expanded programme on immunization. Global advisory group. Wkly Epidemiol Rec. 1992;67:11–6.

21.

Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis. 2012;16(2):e82–8. https://doi.org/10.1016/j.ijid.2011.10.009.CrossRefPubMed

22.

Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.CrossRef

23.

Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis. 2016;20(4):607–28.CrossRef

24.

Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia–Pacific region. J Gastroenterol Hepatol. 2000;15:E3–E6.CrossRef

25.

Basuni AA, Butterworth L, Cooksley G, Locarnini S, Carman WF. Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries. Vaccine. 2004;22:2791–9. https://doi.org/10.1016/j.vaccine.2004.01.046.CrossRefPubMed

26.

Fitzsimons D, François G, Hall A, McMahon B, Meheus A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 2005;23:4158–66. https://doi.org/10.1016/j.vaccine.2005.03.017.CrossRefPubMed

27.

Viviani S, Jack A, Hall AJ, Maine N, Mendy M, et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine. 1999;17:2946–50. https://doi.org/10.1016/S0264-410X(99)00178-4.CrossRefPubMed

28.

Komas NP, Vickos U, Hübschen JM, Béré A, Manirakiza A, et al. Cross-sectional study of hepatitis B virus infection in rural communities, Central African Republic. BMC Infect Dis. 2013;13:286.CrossRef

29.

Lee KM, Kim YS, Ko YY, Yoo BM, Lee KJ, et al. Emergence of vaccine-induced escape mutant of hepatitis B virus with multiple surface gene mutations in a Korean child. J Korean Med Sci. 2001;16(3):359–62. https://doi.org/10.3346/jkms.2001.16.3.359.CrossRefPubMedPubMedCentral

30.

Lin YM, Jow GM, Mu SC, Chen BF. Naturally occurring hepatitis B virus B‑cell and T‑cell epitope mutants in hepatitis B vaccinated children. ScientificWorldJournal. 2013;2013:571875. https://doi.org/10.1155/2013/571875.CrossRefPubMedPubMedCentral

31.

Kabir A, Alavian SM, Ahanchi N, Malekzadeh R. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. Hepatol Res. 2006;36(4):265–71. https://doi.org/10.1016/j.hepres.2006.08.001.CrossRefPubMed

32.

Esteghamati A, Keshtkar AA, Nadjafi L, Gouya MM, Salaramoli M, Roshandel G, et al. Hepatitis B vaccination coverage among Iranian children aged 15–26 months in 2006. East Mediterr Health J. 2011;17(2):93–100.CrossRef

33.

Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403–6. https://doi.org/10.1111/j.1542-4758.2008.00284.x.CrossRefPubMed

34.

Alavian SM, Hajariazdeh B, Ahmadzad Asl M, Kabir A, Bagheri Lankarani KB. Hepatitis B virus infection in Iran: a systematic review. Hepat Mon. 2008;8(4):281–94.

35.

Li T, Fu Y, Allain J‑P, Li C. Chronic and occult hepatitis B virus infections in the vaccinated Chinese population. Ann Blood. 2017; https://doi.org/10.21037/aob.2017.04.02.CrossRef

36.

Fortuin M, Karthigesu V, Allison L, Howard C, Hoare S, et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis. 1994;169:1374–6.CrossRef

37.

Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164:30–40.CrossRef

38.

Yokoyama K, Kumagai H, Takahashi M, Nagashima S, Okamoto H, Yamagata T. Occult hepatitis B virus infection in immunized children born to carrier mothers. Pediatr Int. 2017;59(9):1010–6.CrossRef

39.

Amponsah-Dacosta E, Lebelo RL, Rakgole JN, Selabe SG, Gededzha MP, et al. Hepatitis B virus infection in postvaccination South Africa: occult HBV infection and circulating surface gene variants. J Clin Virol. 2015;63:12–7. https://doi.org/10.1016/j.jcv.2014.11.032.CrossRefPubMed

40.

Mu SC, Lin YM, Jow GM, Chen BF. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J Hepatol. 2009;50(2):264–72. https://doi.org/10.1016/j.jhep.2008.09.017.CrossRefPubMed

41.

Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination program in Taiwan. Gut. 2004;53(10):1499–503. https://doi.org/10.1136/gut.2003.034223.CrossRefPubMedPubMedCentral

42.

Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology. 1999;30(5):1312–7. https://doi.org/10.1002/hep.510300511.CrossRefPubMed

43.

Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol. 2012;57(4):730–5. https://doi.org/10.1016/j.jhep.2012.05.021.CrossRefPubMed

44.

Darmawan E, Turyadi, El-Khobar KE, Nursanty NK, Thedja MD, Muljono DH. Seroepidemiology and occult hepatitis B virus infection in young adults in Banjarmasin, Indonesia. J Med Virol. 2015;87(2):199–207. https://doi.org/10.1002/jmv.24045.CrossRefPubMed

45.

Elrashidy H, El-Didamony G, Elbahrawy A, Hashim A, Alashker A, et al. Absence of occult hepatitis B virus infection in sera of diabetic children and adolescents following hepatitis B vaccination. Hum Vaccin Immunother. 2014;10(8):2336–41. https://doi.org/10.4161/hv.29521.CrossRefPubMedPubMedCentral

46.

Lai MW, Lin TY, Tsao KC, Huang CG, Hsiao MJ, et al. Increased seroprevalence of HBV DNA with mutations in the S gene among individuals greater than 18 years old after complete vaccination. Gastroenterology. 2012;143(2):400–7. https://doi.org/10.1053/j.gastro.2012.05.002.CrossRefPubMed

47.

Aghasadeghi MR, Velayati AA, Mamishi S, Nabavi M, Aghakhani A, et al. Low prevalence of hepatitis B vaccine escape mutants among individuals born after the initiation of a nationwide vaccination program in Iran. Arch Virol. 2016;161(12):3405–11. https://doi.org/10.1007/s00705-016-3050-1.CrossRefPubMed

Titel: No evidence of occult HBV infection in population born after mass vaccination
verfasst von: Mohammad Reza Aghasadeghi
Arezoo Aghakhani
Setareh Mamishi
Farahnaz Bidari-Zerehpoosh
Mohammad-Taghi Haghi Ashtiani
Shahram Sabeti
Mohammad Banifazl
Afsaneh Karami
Anahita Bavand
Amitis Ramezani
Publikationsdatum: 09.04.2020
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 9-10/2020
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-020-00748-z

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9-10/2020

Health concepts of elementary school pupils in Austria

Epidemiologic and clinical findings of children with acquired immunodeficiency syndrome in four provinces of Iran

Dementia diagnostics in general practitioner care

Adolf Lorenz und Tomáš Garrigue Masaryk – eine außergewöhnliche Begegnung

Kommentar zu Brief von Theodor Billroth an Leopold Wittelshöfer vom 22.02.1871

My best case: homeopathic management of adverse effects of tamoxifen